Two-year results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux–M alone, Depatux-M combined with temozolomide (TMZ) and either TMZ or lomustine in recurrent EGFR amplified glioblastoma (NCT02343406),

Name: Two-year results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux–M alone, Depatux-M combined with temozolomide (TMZ) and either TMZ or lomustine in recurrent EGFR amplified glioblastoma (NCT02343406),
Uploaded: 2019-06-21T16:22:43-04:00
Duration: PT668.0S
Description: Two-year results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux–M alone, Depatux-M combined with temozolomide (TMZ) and either TMZ or lomustine in recurrent EGFR amplified glioblastoma (NCT02343406), van de Bent M

Two-year results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux–M alone, Depatux-M combined with temozolomide (TMZ) and either TMZ or lomustine in recurrent EGFR amplified glioblastoma (NCT02343406), van de Bent M

Duration: 11:08

Posted: Friday, June 21, 2019

Video tags: Clinical Trials